Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search


PHARMAC, Novartis reach agreement on Glivec

PHARMAC, Novartis reach provisional agreement on Glivec

PHARMAC has reached a provisional agreement with Novartis to fund the cancer drug Glivec for a wide group of New Zealanders.

PHARMAC is asking for submissions on its funding proposal, which involves a number of products and is subject to the outcome of consultation and final approval by the PHARMAC Board.

Features of the proposal include:

Funding for all patients with interferon-intolerant chronic phase chronic myeloid leukaemia (CML), and for CML patients in accelerated and blast crisis phases (about 90 people) when approved by Medsafe, funding for Glivec as first line therapy for all CML patients (about 85 further people) funding for all patients with unresectable and/or metastatic gastro-intestinal stromal tumours (GIST) (about 30 people)

“Negotiations on Glivec have been a high priority for PHARMAC and we have been working to reach an agreement as quickly as possible,” says PHARMAC Chief Executive Wayne McNee.

“This provisional agreement is the result of a lot of hard work by staff at both PHARMAC and Novartis.”

“Our negotiations with Novartis have enabled us to reach conditional agreement on a proposal to fund Glivec for all those patients for whom it is currently approved in New Zealand. In addition, PHARMAC is proposing to fund Glivec as a first line therapy for CML patients in chronic phase, if the drug is approved for this by Medsafe.”

“We are pleased to have reached this stage and we now want to hear the views of clinicians and the wider public before making a decision.”

PHARMAC will be considering all responses before taking a recommendation to the PHARMAC Board in October. The proposal includes 11 different products used in both community and hospital settings and involves both rebates and price reductions.

If approved by the PHARMAC Board, Glivec would be available fully funded from 1 December 2002.

PHARMAC is also proposing to implement a recommendation of the Cancer Treatments sub-committee of PTAC that treatment with Glivec can continue until the prescribing specialist decides to stop it.

Details of the proposal are available on the PHARMAC website,

The deadline for consultation to be received by PHARMAC is Friday 18 October.

© Scoop Media

Business Headlines | Sci-Tech Headlines


I Sing The Highway Electric: Charge Net NZ To Connect New Zealand

BMW is turning Middle Earth electric after today announcing a substantial contribution to the charging network Charge Net NZ. This landmark partnership will enable Kiwis to drive their electric vehicles (EVs) right across New Zealand through the installation of a fast charging highway stretching from Kaitaia to Invercargill. More>>


Watch This Space: Mahia Rocket Lab Launch Site Officially Opened

Economic Development Minster Steven Joyce today opened New Zealand’s first orbital launch site, Rocket Lab Launch Complex 1, on the Mahia Peninsula on the North Island’s east coast. More>>


Marketing Rocks!
Ig Nobel Award Winners Assess The Personality Of Rocks

A Massey University marketing lecturer has received the 2016 Ig Nobel Prize for economics for a research project that asked university students to describe the “brand personalities” of three rocks. More>>


Nurofen Promotion: Reckitt Benckiser To Plead Guilty To Misleading Ads

Reckitt Benckiser (New Zealand) intends to plead guilty to charges of misleading consumers over the way it promoted a range of Nurofen products, the Commerce Commission says. More>>


Half A Billion Accounts, Including Xtra: Yahoo Confirms Huge Data Breach

The account information may have included names, email addresses, telephone numbers, dates of birth, hashed passwords (the vast majority with bcrypt) and, in some cases, encrypted or unencrypted security questions and answers. More>>


Rural Branches: Westpac To Close 19 Branches, ANZ Looks At 7

Westpac confirms it will close nineteen branches across the country; ANZ closes its Ngaruawahia branch and is consulting on plans to close six more branches; The bank workers union says many of its members are nervous about their futures and asking ... More>>

Interest Rates: RBNZ's Wheeler Keeps OCR At 2%

Reserve Bank governor Graeme Wheeler kept the official cash rate at 2 percent and said more easing will be needed to get inflation back within the target band. More>>


Get More From Scoop

Search Scoop  
Powered by Vodafone
NZ independent news